Topigen Pharmaceuticals focused on the discovery and the development of novel therapeutics for the treatment of respiratory disorders including asthma and COPD. Topigen was developing a clinical pipeline of innovative therapeutics based on its proprietary unique, multi-targeted oligonucleotide technology. Topigen was acquired by Pharmaxis in 2010.